NCT04473170View on ClinicalTrials.gov

Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

146

Participants

Timeline

Start Date

April 4, 2020

Primary Completion Date

May 20, 2020

Study Completion Date

July 14, 2020

Conditions

Coronavirus Disease 2019 (COVID-19)

Interventions

BIOLOGICAL

Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)

SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.

DRUG

COVID-19 standard care

UAE National Guidelines for Clinical Management and Treatment of COVID-19.

Trial Locations (1)

4600

Abu Dhabi Stem Cells Center, Abu Dhabi

All Listed Sponsors

lead

Abu Dhabi Stem Cells Center

OTHER_GOV

NCT04473170 - Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19 | Biotech Hunter | Biotech Hunter